Chongqing Precision Biotech Co., Ltd: Leukemia trials
The registry lists 10 Leukemia studies with Chongqing Precision Biotech Co., Ltd as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 1 10Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Phase 1
- Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT04272125Phase 1/2
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmCompletedNCT06006403Phase 1/2
- Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsCompletedNCT04888468Phase 1
- Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLStatus unknownNCT04888442Phase 1
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
- CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04265963Phase 1/2